

Original Article



Safety of Laparoscopic Radical Gastrectomy in Gastric Cancer Patients with End-Stage Renal Disease

Hayemin Lee , Cho Hyun Park , Seung Man Park, Wook Kim , Hyung Min Chin, Jin Jo Kim , Kyo Young Song , Sung Geun Kim , Kyong Hwa Jun, Jeong Goo Kim, Han Hong Lee , Junhyun Lee, Dong Jin Kim

Department of Surgery, The Catholic University of Korea St. Paul's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea

OPEN ACCESS

Received: Jul 10, 2018
Revised: Aug 25, 2018
Accepted: Sep 6, 2018

Correspondence to

Dong Jin Kim

Department of Surgery, The Catholic University of Korea St. Paul's Hospital, The Catholic University of Korea College of Medicine, 180 Wangsan-ro, Dongdaemun-gu, Seoul 02559, Korea.

E-mail: djdcap@catholic.ac.kr

Copyright © 2018. Korean Gastric Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Hayemin Lee

<https://orcid.org/0000-0003-1057-0157>

Cho Hyun Park

<https://orcid.org/0000-0002-9216-2394>

Wook Kim

<https://orcid.org/0000-0003-3841-4017>

Jin Jo Kim

<https://orcid.org/0000-0003-1011-8793>

Kyo Young Song

<https://orcid.org/0000-0002-5840-1638>

Sung Geun Kim

<https://orcid.org/0000-0002-3087-9728>

Han Hong Lee

<https://orcid.org/0000-0002-7541-8490>

Dong Jin Kim

<https://orcid.org/0000-0001-5103-5607>

ABSTRACT

Purpose: The surgical outcomes of end-stage renal disease (ESRD) patients undergoing radical gastrectomy for gastric cancer were inferior compared with those of non-ESRD patients.

This study aimed to evaluate the short- and long-term surgical outcomes of ESRD patients undergoing laparoscopic gastrectomy (LG) and open gastrectomy (OG) for gastric cancer.

Materials and Methods: Between 2004 and 2014, 38 patients (OG: 21 patients, LG: 17 patients) with ESRD underwent gastrectomy for gastric cancer. Comparisons were made based on the clinicopathological characteristics, surgical outcomes, and long-term survival rates.

Results: No significant differences were noted in the clinicopathological characteristics of either group. LG patients had lower estimated blood loss volumes than OG patients (LG vs. OG: 94 vs. 275 mL, $P=0.005$). The operation time and postoperative hospital stay were similar in both the groups. The postoperative morbidity for LG and OG patients was 41.1% and 33.3%, respectively ($P=0.873$). No significant difference was observed in the long-term overall survival rates between the 2 groups (5-year overall survival, LG vs. OG: 82.4% vs. 64.7%, $P=0.947$).

Conclusions: In ESRD patients, LG yielded non-inferior short- and long-term surgical outcomes compared to OG. Laparoscopic procedures might be safely adopted for ESRD patients who can benefit from the advantages of minimally invasive surgery.

Keywords: Stomach neoplasms; Gastrectomy; Laparoscopy; Kidney failure

INTRODUCTION

Although the incidence of gastric cancer is slightly decreasing, it is still one of the most common malignancies and a major cause of cancer-related death in Korea [1,2]. However, biannual cancer screening programs have identified a large proportion of early-stage gastric cancer patients and increased their overall survival rate. With the increase in survival rates, many surgeons and patients are more focused on the early postoperative recovery and quality of life. Therefore, there has been an increase in the incidence of laparoscopic gastrectomy (LG) than open gastrectomy (OG) [3,4].

End-stage renal disease (ESRD) can be cured with renal transplantation. Through the development of dialysis techniques and kidney transplantation, the total survival rate of ESRD patients has increased. However, some patients with ESRD develop gastric cancer.

Author Contributions

Conceptualization: K.D.J, L.J.; Data curation: L.H, J.K.H.; Formal analysis: K.S.G, L.H.H.; Investigation: L.H, K.D.J, K.J.G.; Methodology: K.J.J, S.K.Y, L.J.; Project administration: K.J.J, K.D.J.; Supervision: P.C.H, P.S.M, K.W, C.H.M.; Visualization: L.H, K.D.J.; Writing - original draft: L.H, K.D.J.; Writing - review & editing: L.H, K.D.J.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

ESRD patients were once regarded as high-risk patients for any operative procedure [5-10]. If the advantages of a laparoscopic approach can be adopted for gastric cancer patients with ESRD, surgical results can be improved. However, the intra-abdominal CO₂ gas insufflation and long duration of high pneumoperitoneum pressure might affect the hemodynamic status and postoperative course of ESRD patients who cannot continuously modulate their volume status. In addition, their tissue status and wound healing processes may be weakened. No study currently addresses the role of laparoscopic radical gastrectomy in ESRD patients. Therefore, this study aimed to evaluate both the short- and long-term surgical outcomes of ESRD patients undergoing LG and OG.

MATERIALS AND METHODS**Patients**

From January 2004 to November 2014, 38 ESRD patients in 7 hospitals affiliated with the Catholic Medical Center in South Korea underwent radical gastrectomy due to gastric adenocarcinoma. They were divided into the LG and OG groups, and the surgical approaches were selected based on each surgeon's preference. The surgeries were performed by 7 different surgeons. Each surgeon performed >300 OG and LG cases during the study period.

A patient with oliguria or anuria receiving regular dialysis (hemodialysis [HD] and peritoneal dialysis [PD]) or with a glomerular filtration rate (GFR) of <15 mL/min/1.73 m² based on the most recent laboratory analysis prior to surgery was defined as having ESRD. Patients who underwent palliative or non-curative resection or had a neoplasm in other organs were excluded. The clinicopathological results and early surgical and long-term survival outcomes were compared between the 2 groups. We adopted the Charlson Comorbidity Index (CCMI) to compare various comorbidities of ESRD patients [11]. In 1987, M.E. Charlson developed CCMI, which was the most cited comorbidity index in the literature, and has been validated in a number of studies [12,13]. Ethical approval was obtained from the Institutional Review Board of the Catholic University of Korea College of Medicine (XC17REDE0072).

Operative methods and postoperative evaluations

Gastric resections included total and distal gastrectomies, with D1+ to D2 lymph node dissection (LND) performed according to the third Japanese gastric cancer treatment guidelines [14]. The type of approach and method of reconstruction were selected based on the surgeon's preference and patient's condition. The extent of resection and LND followed the Japanese treatment guidelines. Closed drains were placed in the Morrison's pouch in all patients following surgery. Moreover, surgical outcomes including the clinicopathological characteristics, number of retrieved lymph nodes (LNs), operation time, estimated blood loss volume, morbidity and mortality rates within 30 days postoperatively, time to first oral intake, and length of postoperative hospital stay were assessed based on a prospectively collected database. Postoperative morbidity was classified according to the Clavien-Dindo (CD) classification [15], and the Comprehensive Complication Index (CCI) [16] was calculated to compare the severity of each patient's multiple postoperative complications.

Statistical methods

The statistical analyses were performed using the SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). The collected data are expressed as median values and interquartile ranges (25–75th percentile) for non-parametric continuous variables, means±standard deviations for parametric

continuous variables, and frequencies with percentages for nominal variables. The χ^2 or Fisher's exact test was used for nominal variables. Additionally, the Mann-Whitney U test was used for non-parametric variables, and the Student's t-test was used for parametric continuous variables. A 2-tailed P-value of 0.05 was considered statistically significant. Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test.

RESULTS

A total of 38 patients (OG: 21 patients, LG: 17 patients) were included in this study. They constituted 0.37% of all patients who underwent curative radical gastrectomy from January 2004 to November 2014. No significant differences were noted on the sex, age, body mass index, cause of renal failure, and type of dialysis between the 2 groups. Diabetes was the most common cause of renal failure in both groups (OG: 47.6%, LG: 47.1%). In the OG group, 16 patients (76.2%) underwent HD and 4 patients (19.0%) had PD. Meanwhile, in the LG group, HD and PD were performed in 13 (76.5%) and 3 (17.6%) patients, respectively. No significant difference was observed in the CCMI between the 2 groups (**Table 1**).

Based on the surgical outcomes, there were no differences in the extent of resection, reconstruction type, LND, or number of retrieved LN (**Table 2**). In the LG group, 7 patients underwent laparoscopy-assisted subtotal gastrectomy, 8 underwent totally laparoscopic subtotal gastrectomy, and 2 underwent totally laparoscopic total gastrectomy. LG patients had less estimated blood loss volume (OG vs. LG: 275 vs. 94 mL, $P=0.005$). The operation time (OG vs. LG: 200 vs. 190 minutes, $P=0.340$) and duration of hospital stay (OG vs. LG: 12 vs. 11 days, $P=0.617$) were similar for both groups. Of the 38 patients, 29 patients (76.3%) were on HD, 7 patients (18.4%) were on PD, and the remaining 2 patients started HD in the early postoperative period. The PD patients required longer operation time compared to the HD patients, although this was insignificant (PD vs. HD: 232.1 vs. 210.4 minutes, $P=0.415$). No significant differences were noted in the postoperative complications of PD and HD patients (PD vs. HD: 42.9% vs. 37.9%, $P=1.000$).

Table 1. Patients' characteristics between the 2 groups

Variables	OG (n=21)	LG (n=17)	P
Age (yr)	65.7±9.4	62.1±8.5	0.230
Sex			0.258
Male	18 (85.7)	11 (64.7)	
Female	3 (14.3)	6 (35.3)	
BMI (kg/m ²)	23.0 (21.5–25.1)	22.9 (20.5–25)	0.463
Cause of renal failure			0.552
Hypertension	6 (28.6)	6 (35.3)	
Diabetes	10 (47.6)	8 (47.1)	
Glomerulonephritis	2 (9.5)	3 (17.6)	
Obstructive nephropathy	1 (4.8)	0 (0.0)	
Others	2 (9.5)	0 (0.0)	
Dialysis			0.984
None	1 (4.8)	1 (5.9)	
Hemodialysis	16 (76.2)	13 (76.5)	
Peritoneal dialysis	4 (19.0)	3 (17.6)	
Hemoglobin (g/dL)	10.0±1.8	9.2±2.3	0.237
Creatinine (mg/dL)	7.6±4.0	6.8±3.5	0.502
Tumor size (cm)	3.5 (2.0–5.5)	3.0 (2.0–4.0)	0.480
CCMI	6.0 (5.0–7.0)	6.0 (5.0–6.0)	0.096

Data are shown as mean±standard deviation or number (%).

OG = open gastrectomy; LG = laparoscopic gastrectomy; BMI = body mass index; CCMI = Charlson Comorbidity Index.

Laparoscopic Gastrectomy in Renal Failure

Table 2. Operative outcomes between the 2 groups

Variables	OG (n=21)	LG (n=17)	P
Resection			0.082
Subtotal gastrectomy	12 (57.1)	15 (88.2)	
Total gastrectomy	9 (42.9)	2 (11.8)	
Reconstruction			0.100
B-I	5 (23.8)	5 (29.4)	
B-II	7 (33.3)	10 (58.8)	
Roux-en-Y	9 (42.9)	2 (11.8)	
LN dissection			0.483
D1+	9 (42.9)	9 (52.9)	
D2	12 (57.1)	8 (47.1)	
Retrieved LN	30.0 (24.0–36.0)	26.5 (19.0–36.0)	0.443
Metastatic LN	0 (0–2.0)	0 (0–0)	0.057
Pathologic stage			0.125
IA	8 (38.1)	14 (82.4)	
IB	2 (9.5)	1 (5.9)	
IIA	3 (14.3)	0 (0.0)	
IIB	1 (4.8)	1 (5.9)	
IIIA	4 (19.0)	0 (0.0)	
IIIB	2 (9.5)	1 (5.9)	
IIIC	1 (4.8)	0 (0.0)	
Operation time (min)	200.0 (175.0–290.0)	190.0 (150.0–240.0)	0.340
Blood loss (mL)	275.0 (100.0–400.0)	94.0 (50.0–200.0)	0.005
Hospital stays (days)	12.0 (9.0–18.0)	11.0 (8.0–15.0)	0.617

Values are presented as number (%).

OG = open gastrectomy; LG = laparoscopic gastrectomy; LN = lymph node.

Table 3. Morbidities and mortalities following gastrectomy in 2 modalities


Variables	OG (n=21)	LG (n=17)	P
CDC			0.602
O	14 (66.7)	10 (58.8)	
II	3 (14.3)	2 (11.8)	
IIIa	1 (4.8)	3 (17.6)	
IIIb	0 (0.0)	1 (5.9)	
IVa	1 (4.8)	0 (0.0)	
V	2 (9.5)	1 (5.9)	
CCI	9.5±17.1	11.7±16.8	0.711
Morbidity*	7 (33.3)	7 (41.1)	0.873
Local			
Gastric stasis	1	0	
Anastomosis bleeding	0	2	
Anastomosis leakage	0	1	
Duodenal stump leakage	1	1†	
Intra-abdominal bleeding	1†	0	
Chylous ascites	0	1	
Systemic			
Infectious complications			
Bacteremia	2	0	
Candidemia	1†	0	
Pulmonary	0	1	
Delirium	1	1	
Mortality	2 (9.5)	1 (5.9)	1.000

Data are shown as mean±standard deviation or number (%).

OG = open gastrectomy; LG = laparoscopic gastrectomy; CDC = Clavien-Dindo classification; CCI = Comprehensive Complication Index.

*Complications more than CDC II; †mortality case.

7 patients (OG vs. LG: 33.3% vs. 41.2%, P=0.873) from each group developed postoperative complications (**Table 3**). Complications were observed in 4 patients (19.0%) in the OG group and 5 patients (29.4%) in the LG group, which were classified as CD grade IIIa or higher.



No. at risk							
Open group	21	15	12	11	9	7	7
Laparoscopy group	17	13	10	10	10	8	5

Fig. 1. No difference in the overall survival between LG and OG was detected. LG = laparoscopic gastrectomy; OG = open gastrectomy.

With the exception of a mortality case, there were 2 cases of morbidity in the OG group: duodenal stump leakage and bacteremia caused by methicillin-resistant *Staphylococcus aureus* (MRSA). In the LG group, 1 patient each developed anastomosis leakage and bleeding, pleural effusion, and chylous ascites. Wound infection was observed in 19.0% (n=4) of the OG group and 11.8% (n=2) of the LG group. Of these patients, wound infection of 1 patient in the OG group was classified as CD grade IIIa, and complications of the remaining 5 patients were CD grade II. The CCI for each group was similar (OG vs. LG: 9.5±17.1 vs. 11.7±16.8, P=0.711). Postoperative mortality was noted in 2 cases in the OG group and 1 case in the LG group. In 2 OG patients, the causes of death were postoperative recurrent intra-abdominal bleeding due to candida infection and multi-organ failure caused by MRSA infection. 1 patient in the LG group expired because of septic shock during duodenal stump leakage.

Survival result

No significant difference was noted in the overall survival between the 2 groups (**Fig. 1**, P=0.947). The 3-year overall survival rate was 82.4% in the LG group and 71.4% in the OG group. Moreover, the 5-year overall survival rate was 82.4% in the LG group and 64.7% in the OG group. The median follow-up period was 51 months (range: 5–122 months). During the follow-up period, 14 patients (36.8%) died (8 in the OG group, 6 in the LG group). 2 patients in each group died because of gastric cancer. Among them, 3 patients died of immediate postoperative complications and 1 died of gastric cancer recurrence. Additionally, 5 OG patients and 4 LG patients died of aggravated renal failure. 1 patient died of prostatic cancer 94 months following gastrectomy (**Table 4**).

Table 4. Causes of death after surgery in gastric cancer patients with ESRD

Cause of death	OG (n=8)	LG (n=6)
Gastric cancer	2	2
Renal failure	5	4
Other malignancy	1*	0
Unknown	1	0

ESRD = end-stage renal disease; OG = open gastrectomy; LG = laparoscopic gastrectomy.

*Prostate cancer.

DISCUSSION

In the present study, laparoscopic radical gastrectomy in ESRD patients was not inferior to OG in terms of the short- and long-term survival results. LG had less intraoperative blood loss volume; however, both groups involved LND and had a similar extent of resection. The operation time, duration of hospital stay, postoperative morbidity, and long-term survival rate were similar in both groups. In general, ESRD is considered to be a major risk factor for postoperative morbidity and mortality in major abdominal surgeries [5-7,10,17]. The morbidity rate of all ESRD patients in our study was 36.8%. This rate is higher than that of non-ESRD patients in previous reports, ranging from 14.7%–21.2% [18-20]. Although LG is a popular procedure for patients with gastric cancer regardless of the stage, its influence in chronic kidney disease (CKD) or ESRD patients has not been reported. In this study, we focused on analyzing the safety and oncologic feasibility of LG in ESRD patients with impaired hemostatic function and wound healing undergoing radical LND and bowel anastomosis.

Matsumoto et al. [18] reported that the severity of CKD was associated with an increase in surgical complications and a higher surgical mortality rate following radical gastrectomy. They classified 177 patients with CKD into 2 groups according to GFR (mild CKD: GFR of 30–59 mL/min/1.73 m²; severe CKD: GFR <29 mL/min/1.73 m²). Systemic complications and in-hospital mortality increased as the CKD stages became more severe. Anastomosis leakage, intra-abdominal abscess, and wound infection were more common in both CKD groups. LG was performed in 29 patients (16.3%) and was not associated with severe postoperative complications. A recent study comparing 108 patients divided into the CKD and non-CKD group demonstrated the influence of this disease on gastric cancer surgery [19]. The CKD group was defined as patients with an estimated GFR (eGFR) of <60 mL/min/1.73 m². The CKD patients showed no significant differences compared with the non-CKD group. The relapse-free survival rates of the 2 groups were similar but only 13 patients from this study had severe CKD (eGFR <30 mL/min/1.73 m²). Another study retrospectively analyzed 26 patients with ESRD after radical gastrectomy; however, no information on laparoscopic procedures was shown [20]. To the best of our knowledge, this study is the first to analyze the safety of laparoscopic radical gastrectomy in ESRD patients.

ESRD patients have underlying cardiovascular comorbidities such as hypertension, atherosclerosis, and hyperlipidemia. They are known to be vulnerable to major perioperative cardiac complications [18,21]. Patients who underwent LG will endure high pneumoperitoneum pressure during the operation; therefore, they are exposed to perioperative hemodynamic instability and pulmonary complications. However, the effect of intra-abdominal CO₂ gas insufflation on CKD patients has not been investigated. In the present study, no major cardiac complications occurred in either LG or OG group, and only 1 patient in the LG group had a pleural effusion requiring percutaneous drainage. Although more studies are required, ESRD patients seem to tolerate intra-abdominal CO₂ gas insufflation for about 200 minutes of laparoscopic procedure. Uremia and malnutrition in ESRD patients cause platelet dysfunction that leads to decreased hemostatic function [19,22]. Intraluminal anastomosis bleeding occurred in 2 (11.8%) LG patients and 1 OG patient expired due to recurrent bleeding after the third operation. Moreover, increased bleeding tendency in ESRD patients increases the difficulty of D2 LND. The technical feasibility, safety, and oncological outcome of LND up to the D2 level is challenging for surgeons, especially in advanced gastric cancer. Approximately 52.6% underwent D2 LND and an adequate number of patients with LN (OG: 30.0%, LG: 26.5%) were retrieved. However, the safety of radical LND in ESRD patients should be validated by further studies.

Liu et al. [20] reported that one of the major causes of complications in 26 ESRD patients undergoing radical gastrectomy is anastomosis leakage. The rate of anastomotic leakage in CKD patients was more than two-fold that of the normal population, and CKD was also an independent risk factor for esophagojejunal anastomotic leakage. In our study, 1 case of esophagojejunostomy leak after LG (5.9%) was observed, and each group had 1 patient with duodenal stump leak (OG: 4.8%, LG: 5.7%). In this case, the LG patient died. With the immune response deficiency in ESRD patients, the anastomotic leakage easily leads to fulminant infections. Surgeons should pay attention when performing the anastomosis in gastrectomies involving ESRD patients, especially when performing esophagojejunostomy in total gastrectomy.

Seven patients (18.4%), including 4 in the OG group and 3 in the LG group, were on PD at the time of gastrectomy, and although insignificant, the PD patients required longer operation time compared with the HD patients. This may be caused by the presence of intra-abdominal adhesions induced by repetitive PD and handling of the indwelling PD catheter. The incidence of postoperative complications was similar in both groups (PD vs. HD: 42.9% vs. 37.9%, $P=1.000$) but 2 OG patients who expired were on PD. 1 LG patient showed chylous ascites through a closed drain that spontaneously improved with a low-fat diet. 1 patient from each group did not have the PD catheter removed during the gastrectomy and resumed PD after the operation. The patient who underwent LG was admitted 1 year after gastrectomy due to an adhesive ileus that was managed conservatively. A recent review cited that the use of laparoscopic techniques was effective in continuing PD in the early postoperative period by reducing peritoneal membrane stress, preserving peritoneum integrity, and decreasing the risk of postoperative dialysis fluid leakage [23].

Iannuzzi et al. [17] analyzed the database from the American College of Surgeons National Surgical Quality Improvement Program in 2013 and reported that bowel resection in patients with ESRD conferred a high mortality risk and that laparoscopy was associated with a reduced postoperative morbidity. Although most parts of this study include both small bowel and colon surgery, the authors presumed that laparoscopic surgery resulted in an attenuated surgical stress response and better preservation of the cell-mediated immune response. Furthermore, it is associated with a quicker return to baseline through reduced postoperative pain, earlier mobilization, and return of bowel function. Although the only significant advantage in the present study was the reduction of intraoperative blood loss volume, there were some better outcomes in operation time and postoperative hospital stay. Some positive influences of LG in the postoperative outcomes of ESRD patients can be found. With innovations in minimally invasive surgery, more favorable evidence will be gathered on the effects of LG on ESRD patients.

In the survival analysis, there was little difference between the 2 groups ($P=0.947$). The main causes of death were caused by the complications of ESRD or early surgical mortalities, not the recurrence of carcinoma (Table 4). This result demonstrates that limited LND and resection in ESRD patients seem to be more reasonable than performing an extensive radical procedure that strictly follows the guidelines. ESRD itself has a poor prognosis, with the average survival of 60-year-old patients with ESRD reported as 5.5 years and that of 65-year-old patients as 4.3 years [24]. In this aspect, laparoscopic procedures can provide better safety to ESRD patients without compromising long-term survival or prognosis.

There are some limitations to our study. First, a relatively small number of patients were enrolled. Second, the number of surgeons that participated in our study was relatively large

in relation to the number of patients. The disparity of the surgeons' surgical skills may have affected the consistency of surgical outcomes. Third, the OG group had a relatively large proportion of advanced stage gastric cancer patients and patients who underwent total gastrectomy. These factors introduced a degree of heterogeneity of surgical procedure and might influence the short- and long-term surgical outcomes. Finally, the study was designed retrospectively. Study limitations are probably attributed to the paucity of operable gastric cancer patients with ESRD. To date, this study includes the highest number of ESRD patients who underwent radical gastrectomy. With more experience and well-designed multi-centered studies, the influence of LG on ESRD will be more clearly elucidated.

In conclusion, LG showed comparable short- and long-term surgical outcomes in ESRD patients than OG. With careful consideration in terms of patient selection and preparation for operation, laparoscopic procedures might be safely adopted in ESRD patients so they can benefit from the advantages of minimally invasive surgery.

REFERENCES

1. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Prediction of cancer incidence and mortality in Korea, 2014. *Cancer Res Treat* 2014;46:124-130.
[PUBMED](#) | [CROSSREF](#)
2. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. *Cancer Res Treat* 2014;46:109-123.
[PUBMED](#) | [CROSSREF](#)
3. Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. *J Clin Oncol* 2014;32:627-633.
[PUBMED](#) | [CROSSREF](#)
4. Kim YW, Baik YH, Yun YH, Nam BH, Kim DH, Choi IJ, et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. *Ann Surg* 2008;248:721-727.
[PUBMED](#) | [CROSSREF](#)
5. Borlase B, Simon JS, Hermann G. Abdominal surgery in patients undergoing chronic hemodialysis. *Surgery* 1987;102:15-18.
[PUBMED](#)
6. Wind P, Douard R, Rouzier R, Berger A, Bony C, Cugnenc PH. Abdominal surgery in chronic hemodialysis patients. *Am Surg* 1999;65:347-351.
[PUBMED](#)
7. Toh Y, Yano K, Takesue F, Korenaga D, Maekawa S, Muto Y, et al. Abdominal surgery for patients on maintenance hemodialysis. *Surg Today* 1998;28:268-272.
[PUBMED](#) | [CROSSREF](#)
8. Devbhandari MP, Duncan AJ, Grayson AD, Fabri BM, Keenan DJ, Bridgewater B, et al. Effect of risk-adjusted, non-dialysis-dependent renal dysfunction on mortality and morbidity following coronary artery bypass surgery: a multi-centre study. *Eur J Cardiothorac Surg* 2006;29:964-970.
[PUBMED](#) | [CROSSREF](#)
9. Cooper WA, O'Brien SM, Thourani VH, Guyton RA, Bridges CR, Szczech LA, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the society of thoracic surgeons national adult cardiac database. *Circulation* 2006;113:1063-1070.
[PUBMED](#) | [CROSSREF](#)
10. Cloyd JM, Ma Y, Morton JM, Kurella Tamura M, Poultsides GA, Visser BC. Does chronic kidney disease affect outcomes after major abdominal surgery? results from the national surgical quality improvement program. *J Gastrointest Surg* 2014;18:605-612.
[PUBMED](#) | [CROSSREF](#)
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-383.
[PUBMED](#) | [CROSSREF](#)

12. Malenka DJ, McLerran D, Roos N, Fisher ES, Wennberg JE. Using administrative data to describe casemix: a comparison with the medical record. *J Clin Epidemiol* 1994;47:1027-1032.
[PUBMED](#) | [CROSSREF](#)
13. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol* 2011;173:676-682.
[PUBMED](#) | [CROSSREF](#)
14. Sano T, Kodera Y; Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. *Gastric Cancer* 2011;14:101-112.
[PUBMED](#) | [CROSSREF](#)
15. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg* 2009;250:187-196.
[PUBMED](#) | [CROSSREF](#)
16. Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. *Ann Surg* 2013;258:1-7.
[PUBMED](#) | [CROSSREF](#)
17. Iannuzzi JC, Deeb AP, Rickles AS, Sharma A, Fleming FJ, Monson JR. Recognizing risk: bowel resection in the chronic renal failure population. *J Gastrointest Surg* 2013;17:188-194.
[PUBMED](#) | [CROSSREF](#)
18. Matsumoto S, Takayama T, Wakatsuki K, Tanaka T, Migita K, Nakajima Y. Short-term and long-term outcomes after gastrectomy for gastric cancer in patients with chronic kidney disease. *World J Surg* 2014;38:1453-1460.
[PUBMED](#) | [CROSSREF](#)
19. Wakahara T, Ueno N, Komatsu S, Ashitani H, Tsuchida S, Toyokawa A. Outcome of gastric cancer surgery in patients with chronic kidney disease. *Dig Surg* 2017;34:241-246.
[PUBMED](#) | [CROSSREF](#)
20. Liu YY, Tsai CY, Yeh CN, Chiang KC, Wang SY, Cheng CT, et al. Gastric cancer patients with end-stage renal disease who underwent radical gastrectomy. *Anticancer Res* 2015;35:2263-2268.
[PUBMED](#)
21. Craig RG, Hunter JM. Recent developments in the perioperative management of adult patients with chronic kidney disease. *Br J Anaesth* 2008;101:296-310.
[PUBMED](#) | [CROSSREF](#)
22. Acedillo RR, Shah M, Devereaux PJ, Li L, Iansavichus AV, Walsh M, et al. The risk of perioperative bleeding in patients with chronic kidney disease: a systematic review and meta-analysis. *Ann Surg* 2013;258:901-913.
[PUBMED](#) | [CROSSREF](#)
23. Mari G, Scanziani R, Auricchio S, Crippa J, Maggioni D. Laparoscopic surgery in patients on peritoneal dialysis: a review of the literature. *Surg Innov* 2017;24:397-401.
[PUBMED](#) | [CROSSREF](#)
24. van Walraven C, Manuel DG, Knoll G. Survival trends in ESRD patients compared with the general population in the United States. *Am J Kidney Dis* 2014;63:491-499.
[PUBMED](#) | [CROSSREF](#)